1. Apabetalone (RVX-208) attenuates hyperglycemia and tmao induced adhesion of THP-1 monocytes to Huvec endothelial cells. (August 2018) Authors: Tsujikawa, L.; Kulikowski, E.; Calosing, C.; Wasiak, S.; Gilham, D.; Halliday, C.; Johansson, J.; Sweeney, M.; Wong, N. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Apabetalone (RVX-208) decreases atherogenic, thrombotic and inflammatory mediators in vitro and in plasma of patients with cardiovascular disease (CVD). (September 2016) Authors: Wong, N.; Kulikowski, E.; Wasiak, S.; Gilham, D.; Calosing, C.; Laura, T.; Halliday, C.; Johansson, J.; Sweeney, M. Journal: Atherosclerosis Issue: Volume 252(2016) Page Start: e245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The investigational drug ZEN-3694, a novel BET-bromodomain inhibitor, inhibits multiple tumor immune escape mechanisms and has the potential to combine with immunotherapies. (December 2016) Authors: Attwell, S.; Norek, K.; Jahagirdar, R.; Calosing, C.; Lakhotia, S.; Campeau, E.; Hansen, H. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗